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Introduction
Over the past 30 years, wild-type AAVs have been engineered to create recombinant AAV vectors, which have proven to be exceptionally useful tools for gene transfer into the CNS 1, 2, 3, 4, 5, 6 and gene therapy approaches to disease (including FDA-and EMA-approved therapies) 4, 7 . Their suitability for use in the CNS largely derives from their ability to infect non-dividing, post-mitotic cells, typically found in the CNS 8 . However, AAVbased vectors also have the advantage of allowing a long-term expression of any given therapeutic transgene 4, 9 while eliciting a milder immune response compared to other viral vectors 7, 8, 10, 11, 12 .
The main elements of any AAV vector are the genome and the capsid. Wild-type AAVs are single-stranded (ss) DNA viruses with a genome of approximately 5 kilobases (kb) 13 . For the production of recombinant AAV vectors, the rep and cap genes (necessary for genome replication and the assembly of the viral capsid) are deleted from the genome of the wild-type AAV and provided in trans, leaving room for an expression cassette containing the transgene 14, 15 . The inverted terminal repeat sequences (ITRs) of the original viral genome are the only retained elements in an AAV vector, as these are essential for replication and packaging 3, 10, 14 . AAV vectors can be engineered to enhance transgene expression; a mutation in one of the ITRs leads to the formation of a hairpin loop which effectively allows the generation of a complementary DNA strand 3, 7, 15 .
The main advantage of this configuration, termed a self-complementary (sc) genome, is that it bypasses the need for second-strand synthesis typical in the conventional life cycle of AAVs, considerably increasing the speed and levels of transgene expression
The protocol itself is a variant of the classical tri-transfection method for viral vector production and incorporates the use of an iodixanol gradient for vector clean-up, which, in comparison to the classical use of cesium chloride (CsCl) gradients, has been reported to produce AAV vectors of higher purity in a more time-efficient manner 19, 20, 21 .
The transfection, purification and concentration steps are intended to be performed according to good laboratory practice (GLP) in a tissue culture laboratory rated for viral vector work. Each task needs to be performed in compliance with the relevant local and national legislation concerning viral vector production and use. Work must be carried out under a laminar flow hood and in sterile conditions. Inside the vector facility, it is recommended to wear a lab apron, in addition to the regular tissue culture lab coat. Moreover, a double pair of gloves, as well as plastic overshoes, should be worn at all times.
Before starting the vector production, ensure all necessary equipment and plasmids are available. 1) pCapsid plasmid contains the rep gene that encodes four non-structural proteins necessary for replication, namely Rep78, Rep68, Rep52, and Rep40, and the cap gene that encodes three structural capsid proteins, namely VP1, VP2, and VP3. 2) pHelper plasmid contains the genes E4, E2A, and VA from adenovirus, which facilitate AAV production in HEK293T cells. 3) pTransgene plasmid contains the transgene expression cassette, flanked by two ITRs. These plasmids can be synthesized de novo in the laboratory using sequences available online 22 . For plasmids made de novo, especially those containing novel transgenes, sequencing is required, to make sure that the transgene and ITRs are correct. Alternatively, premade plasmids can be directly acquired through online plasmid repositories. When necessary, plasmids can be amplified and purified using standard kits, according to the manufacturer's instructions 23 .
Vector titer and purity can adversely affect the transduction ability of the vector. Additional protocols are supplied to evaluate the quality of the produced vector. The final vectors will be useful for studies of the CNS cell function in both in vitro and in vivo applications. 12. Harvest the medium and the cells 72 h post-transfection. Use a cell scraper to carefully detach the cells from the culture dish. Collect the medium and the cells in a 50 mL conical tube kept on ice. NOTE: The contents of two cell culture dishes can be collected into a single 50 mL conical tube. At the end of this step, each of the nine tubes will contain approximately 50 mL of medium. 13. Centrifuge the conical tubes at 420 x g for 10 min at 4 °C with the acceleration and deceleration of the centrifuge set to maximum. 14. Carefully discard the supernatant from each tube. Do not use pipettes to prevent the loss of material. Instead, gently pour the supernatant into a waste disposal container and place the tubes containing the cell pellets back on the ice. 15. Resuspend each cell pellet in 2 mL of lysis buffer directly in the 50 mL conical tube by pipetting up and down 5-10x. Do not vortex. Pool the lysates from three tubes together. NOTE: At this point, there will be three 50 mL conical tubes, each one containing 6 mL of the resuspended cells in lysis buffer.
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AAV Vector Purification
NOTE: Performance of this protocol section takes approximately 1 day. Perform the following steps simultaneously on each of the three 50 mL conical tubes containing the cells resuspended in lysis buffer (see the previous note).
1. Freeze and thaw the resuspended cells 3x to lyse them and release the AAV particles. Perform the freezing step by placing the tubes in a bucket containing dry ice mixed with ethanol. Perform thawing by immediately placing the cells in a water bath set at 37 °C. 2. After the third thawing step, centrifuge at 1,167 x g for 15 min at 4 °C.
NOTE: A noticeable pellet composed of cell debris will be formed. When handling the tubes, avoid sudden movements as these can cause the detachment of the pellet into the supernatant, which will compromise the purity of the final vector. 3. Carefully transfer the supernatants to clean 50 mL conical tubes and then add nuclease to each tube, to a final concentration of 50 U/mL supernatant. 4. Incubate for 30 min at 37 °C. Swirl the 50 mL conical tubes by hand every 10 min to ensure that the nuclease is thoroughly mixed with the supernatant. 5. Clarify the supernatant by centrifugation at 13,490 x g for 20 min at 4 °C. 6. Attach a 0.45 µm filter to a 10 mL syringe and place it on top of a clean 50 mL conical tube. Carefully remove the plunger and fill the syringe with the supernatant from step 2.5. 7. Use the plunger to force the lysate through the filter. Use a new filter and syringe for each tube of supernatant obtained in step 2.5.
NOTE:
The obtained fraction is known as 'crude lysate'. 8. Prepare each of the 15%, 25%, 40%, and 60% iodixanol fractions in four separate 50 mL conical tubes, according to the instructions in Table  1 . 9. Prepare the iodixanol gradients in three ultracentrifugation tubes using the following order of iodixanol fractions: 8 mL of 15% iodixanol, 5.5 mL of 25% iodixanol, 5 mL of 40% iodixanol, and 4.5 mL of 60% iodixanol. CAUTION: Iodixanol can cause irritation to eyes, skin, and the gastrointestinal and respiratory tracts. When handling iodixanol gradients, wear gloves and work under a laminar flow hood. '. 2. Incubate for 30 min at 37 °C, followed by 10 min at 95 °C.
NOTE: The protocol can be stopped at this point and the material can be stored indefinitely at 4 °C, to avoid product deterioration. 3. Add 2 µL of proteinase K to the dil1 x 10 -2 solution (step 4.2.1) and incubate for 60 min at 50 °C, followed by 20 min at 95 °C.
This step will disassemble the AAV vector capsid and release the AAV vector genome into the solution. Add proteinase K in excess as the protein (capsid) content of the sample is not known. Note, it is essential to ensure that all proteinase K activity is removed by denaturation, prior to qPCR, to avoid issues with (partial) polymerase degradation influencing the final result. 
Titration by SYBR Green detection-based qPCR
1. Prepare the qPCR master mix in a 1.5 mL microcentrifuge tube, for both the sample and the standards. Use 10 µL of SYBR Green Master Mix, 1 µL of forward primer (10 µM stock), 1 µL of reverse primer (10 µM stock), and 3 µL of H 2 O per reaction. See the protocol in Table 4 for primer sequences. 2. Pipette the qPCR master mix up and down, but do not vortex. 3. Add 15 µL of the qPCR master mix, followed by either 5 µL of the standard curve prepared in section 4.1 or the DNA extracted from the AAV vector in section 4.2, into each well. Include three wells containing only the qPCR master mix, as a negative control. Refer to Figure 2 for the plate layout. 4. Seal the plate with a sealing film and briefly centrifuge the qPCR plate at 1,500 x g for 30 s at 4 °C. 5. Run the qPCR reaction on a plate-based real-time PCR amplification and detection instrument, using the conditions suggested in Table  5 .
Primer name Sequence
Forward primer 5'-CCCACTTGGCAGTACATCAA-3'
Reverse primer 5'-GCCAAGTAGGAAAGTCCCAT-3' Step (Table 6B) . A qPCR must have an efficiency close to 100% and R 2 close to 1.0 (≥ 0.96).
. In fact, as DNA quantities double during each qPCR cycle, sc DNA is detected 2x in comparison to an ss genome. The aim of the titration is to calculate the concentration in terms of vector genomes per microliter. A correction is necessary for running the qPCR when using 2 µL of starting material (step 4.2.1). dil represents the dilution factors from step 4.2.4. The titer of the 'secondary' AAV vector fraction (step 3.6) can be calculated simultaneously. 
Purity Control by SDS-PAGE and Silver Staining
NOTE: Performance of this section of the protocol takes approximately 5 h.
1. Use 70% (v/v) ethanol to thoroughly clean the glass plates used for casting the gels. 2. Assemble the gel casting system. Ensure that the bottoms of the glass plates are not chipped, to prevent leakage of the acrylamide mixture when casting the gel. 3. Prepare the stacking and the resolving gel solutions in two separate 50 mL conical tubes. Omit the tetramethylethylenediamine (TEMED) and the 10% (w/v) ammonium persulfate (APS), as they are responsible for polymerization of the gel. Add them immediately before casting the gel.
NOTE:
The final percentage of acrylamide in the gel influences the separation profile of the proteins: typically, a 10% (v/v) final concentration of acrylamide will be sufficient to test the purity of an AAV vector preparation. 4. Mix gently by swirling the tube containing the gel components. Do not vortex, since excessive oxygenation can impair polymerization. 5. Add TEMED and 10% (w/v) APS to the resolving gel solution. Mix and then pour into the gel holder until it reaches 1-2 cm below the top of the small glass plate. 6. Place a layer of water-saturated butanol on the top of the acrylamide mixture. This will ensure the formation of a flat surface during polymerization. Do not leave the gel under alcohol for longer than 30 min as this will dehydrate the gel and impair its function. CAUTION: Butanol is hazardous in case of skin contact. It also presents a fire risk. Handle with care. 7. Wait for the gel to polymerize and then pour off the butanol. Tip: Check to see whether the excess gel mix in the tube has solidified.
Polymerization occurs in less than 20 min. Wash the surface of the gel with H 2 O and then dry it using paper towels, taking care not to disturb the surface of the gel. 8. Add TEMED and 10% (w/v) APS to the stacking gel and pour the gel into the gel holder on top of the separating gel. 9. Place the provided comb in the gel. Perform this action with one steady movement to avoid the formation of air bubbles inside the wells. 10 . Wait for at least 20 min for the gel to polymerize. Tip: Check if the excess gel mix in the conical tube has solidified. 11. Prepare the two mixes (Table 7) for both the primary and the secondary AAV vector fractions (steps 3.5 and 3.6, respectively).
High Amount
Low 12. Fully denature the sample mixes by heating them for 5 min at 95 °C. Assemble the electrophoresis tank, paying attention to the electrode orientation. 13. Fill the tank with 1x cathode buffer on the inside of the electrode assembly and 1x anode buffer on the outside. NOTE: Anode buffer can be recycled from run-to-run. Fresh cathode buffer must always be used. 14. Remove the comb from the gel and clean the wells of the gel with 1x cathode buffer. 15. Load 1 µL of protein ladder in a well. Load the sample mixes in different wells on the same gel (Figure 3 ). Run the gel at 50 V until the samples enter the resolving gel. Then increase the voltage to 100 V until the dye front reaches the lower limit of the gel. 16. Extract the gel carefully from the glass plates and use the silver staining kit (according to the manufacturer's instructions 26 ) to visualize the viral proteins (VP1, VP2, and VP3 subunits) that comprise the AAV capsid, as well as to check for possible protein contamination (Figure 3 ). 
Representative Results
AAV9 was considered, until recently, to be the most effective AAV vector serotype in crossing the BBB and transducing cells of the CNS, following peripheral administration. A significant advance in capsid design was achieved when Deverman et al. reported the use of a capsid selection method called Cre recombination-based AAV-targeted evolution (CREATE) 17 . Using this method, they identified a new capsid, named PHP.B, which they reported as able to transduce the majority of astrocytes and neurons in multiple CNS regions, following systemic injection 17 .
At this point, it should be noted that even though PHP.B provides positive results in C57/Bl6 mice (which was the strain used in the initial isolation experiments), preliminary reports suggest its efficiency may vary in a strain-dependent manner. Further experiments will, no doubt, shed more light on this issue 31 . However, despite these issues, PHP.B offers exciting possibilities for noninvasive gene manipulation in the CNS of mice, including proof-ofconcept gene therapy experiments in disease models. As such, we chose to evaluate the efficiency of transgene expression using PHP.B versus AAV9, which has been the 'gold-standard' vector for CNS transduction following peripheral administration since 2009 2 . To perform a direct comparison of both serotypes, under optimal conditions for transgene expression, we used an sc genome configuration 32 . Both vectors carried the transgene for green fluorescent protein (GFP) under the control of the ubiquitous chicken β-actin (CBA) promoter. Female C57/Bl6 mice at postnatal day 42 (approximately 20 g in weight) received a dose of 1 x 10 12 vg per mouse of either scAAV2/PHP.B-CBA-GFP or scAAV2/9-CBA-GFP. Vector administration was performed via tail vein injection. The experiments were approved by the Ethical Committee of the KU Leuven.
Three weeks postinjection, the mice underwent transcardial perfusion with ice-cold PBS, followed by 4% (w/v) ice-cold paraformaldehyde (PFA). Their brains were harvested and underwent further postfixation by an overnight incubation in the same fixative, before transferring to 0.01% (w/ v) Na-azide/PBS for storage until further analysis. Afterward, the brains were sectioned using a vibrating microtome, and immunohistochemistry was performed on 50 µm thick sections.
To evaluate the levels of transgene expression, sections were stained with primary antibodies against GFP (rabbit anti-GFP), with detection using secondary antibodies conjugated to a fluorescent dye (anti-rabbit Alexa Fluor 488) (Figure 4A, B) . Fluorescence intensity measurements (in arbitrary units [au]) confirmed a significant increase in GFP expression when an sc genome and the PHP.B capsid were used relative to AAV9. Increases in GFP were observed in the cerebrum (2105 ± 161 vs. 1441 ± 99 au; p = 0.0032), the cerebellum (2601 ± 196 vs. 1737 ± 135 au; p = 0.0032), and the brainstem (3082 ± 319 vs. 2485 ± 88 au; p = 0.0038) (Figure 4C ).
Discussion
The production of recombinant AAV vectors described here uses materials and equipment common to most molecular biology labs and cell culture facilities. It allows the user to obtain pure, preclinical grade AAV vectors that can be used to target multiple cell and tissue types across a range of in vitro and in vivo applications. One of the greatest advantages of this protocol, compared to others (i.e., CsCl-based purification), is the shorter working time needed. Ready-to-use AAV vectors are obtainable in a maximum of 6 working days after the initial transfection of HEK293T cells.
Several factors can negatively influence the final yield or the quality of the AAV vector. Poor transfection efficiency is one of the main reasons for a low viral yield 33 . A major recommendation is the use of HEK293T cells that have not been passaged more than 20 times and do not have a cell confluence greater than 90% at the time of transfection 21 . In addition, the transfection method selected has a major impact on the results. This protocol is based on the use of PEI. PEI is a cationic polymer with the ability to deliver exogenous DNA to the cell nucleus through the generation of complexes of polymer and nucleic acid, known as polyplexes, which are taken up by the cell and trafficked via endosomes 34 .
PEI-based transfection is easy and fast to perform, in contrast to other widely used methods, such as the co-precipitation of DNA with calcium phosphate 35 . Also, PEI-based transfection is much cheaper when compared to other newly introduced methods, such as the usage of cationic lipids and magnet-mediated transfection 36 .
The purification strategy plays a key role in the protocol. Compared to other methods, iodixanol-based purifications tend to contain a higher percentage of empty viral particles (20%) 20 . This is offset, to a degree, by the fact that iodixanol-based purification routinely results in AAV vector preparations with a particle-to-infectivity ratio of less than 100. This represents a significant improvement in comparison to conventional CsClbased procedures, for which substantial loss of particle infectivity is reported 37 . Another common alternative method to purify AAV vectors is chromatography-based purification. However, this method has the major drawback that a specific column is required for each vector capsid used: for example, while AAV2 is classically isolated using heparin columns, this methodology does not work with AAV4 and AAV5, which do not possess heparin-binding sites on their capsids 38 . Considering that chromatography purification is also expensive, iodixanol-based purification is generally more suitable for laboratories that wish to produce high-quality batches of AAV vectors on a small scale 33, 39, 40 . However, to maximize the final yield and purity of the vector, extreme care is needed when making the iodixanol gradients. The various iodixanol fractions should be transferred to the ultracentrifugation tube using a sterile Pasteur pipette whose tip is touching the wall of the tube: iodixanol should be expelled from the pipette slowly and continuously. As the vector particles accumulate in the 40% iodixanol layer, care needs to be taken to ensure that the gradient interfaces do not mix 20 . Finally, the fraction containing the vector should be recovered by the insertion of a stainless-steel blunt needle with a gauge not larger than 20 G. To maximize vector recovery, the clear fraction should be retrieved in its entirety. During this step, timing is critical. To avoid compromising the purity of the preparation, it is essential to stop the collection before other (contaminating) phases of the gradient are collected.
Differences in the obtained vector titer can be also attributed to the intrinsic ability of the vector to produce packaged particles. A comparison between different AAV serotypes showed that some AAV vectors are more difficult to produce at a higher titer than others (e.g., AAV2) 41 . Precipitation of the vector, during the desalting step, can be a possible reason for a lower titer and easily prevented by avoiding overconcentration 33 . Moreover, it is also possible that the efficiency of iodixanol gradient-based purification slightly differs between serotypes and, therefore, discrepancies in the titer obtained with different serotypes can be observed 41 .
Finally, it needs to be pointed out that even though qPCR is a very accurate method for DNA quantification some inherent variability in the technique can be observed. Accuracy in the titration primarily depends on the precise pipetting and proper vortexing of all the solutions. To guarantee the most accurate titer reading, the qPCR can be independently repeated, and the obtained values averaged. The choice of primers presented in this protocol is based on the sequence of the CBA promoter located in the pTransgene plasmid used in our laboratory. The CBA promoter is a strong synthetic promoter that is widely used in the vector field to drive expression across multiple cell types. It incorporates multiple elements, including the cytomegalovirus (CMV) early enhancer element; the promoter, first exon, and the first intron of the CBA gene; and the splice acceptor of the rabbit β-globin gene. However, primers can be designed for virtually any element located within the expression cassette (including the promoter, transgene, and regulatory elements). The comparison of titer across batches is also possible, providing primers are used against regions common to the vectors in question.
In conclusion, this protocol can be used to produce AAV vectors with a variety of capsids, genome configurations, promoter types and transgene cargos. This will allow users to easily adapt the final characteristics of their vectors to best suit experimental needs. In the example presented in the representative results, the use of the PHP.B capsid, which efficiently crosses the BBB, gave highly efficient gene expression in the CNS, following tail vein injection 32 . The systemic administration of CNS penetrant vectors has considerable advantages in terms of possible sideeffects 2, 17, 32 . A possible alternative to peripheral injection, while avoiding the caveats of invasive techniques, is intrathecal delivery, which consists of delivery of the AAV vector into the cerebrospinal fluid. This delivery route is proven to be effective, showing widespread expression of transgene across the CNS, less off-target effects in peripheral organs, and low levels of immune response
